On September 30th, Pharmatech continued to rise for 2 consecutive days, Haoyuan Pharmaceutical approached the daily limit, and several stocks such as Sunshine Noron, Pharmaron, Pharma Block Sciences, Porton Pharma Solutions, and Chempartner Pharmatech rose by more than 10%. According to the research reports of Southwest Securities, most CXO leading companies achieved double-digit sequential growth in new signed orders in Q2 2024. Overseas investment and financing have shown improvement since Q3 2023, as we enter an easing cycle, the demand for research and development is recovering, and CXO overseas orders will further rebound.